Ftse Mib
35.047,40
0,71%
DAX
20.266,70
0,64%
S&P 500
5.836,22
0,16%
NASDAQ
19.088,10
-0,38%
Bitcoin
95.692,51
1,25%
Pepperstone
Advertisement
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Ascendis Pharma AS (ASND) Ascendis Pharma AS (ASND) Notizie

Ascendis Pharma AS

ASND
134,04
0,00 (0,00%)
14 Gen 2025 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Ricevuta di Deposito
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
12/1/202523:00GLOBEAscendis Pharma Provides Business and Strategic Roadmap..
06/1/202514:30GLOBEAscendis Pharma to Participate in the 43rd Annual J.P...
30/12/202422:04EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
19/12/202414:30GLOBEYORVIPATH® (Palopegteriparatide) Now Commercially Available..
17/12/202412:04EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
16/12/202414:30GLOBENew InsiGHTS Trial of TransCon™ hGH (Lonapegsomatropin) in..
12/12/202422:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
12/12/202422:01GLOBEFDA Accepts Ascendis Pharma’s Supplemental Biologics License..
11/12/202422:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
10/12/202423:16EDGAR2Form 144 - Report of proposed sale of securities
10/12/202423:07EDGAR2Form 144 - Report of proposed sale of securities
10/12/202423:02EDGAR2Form 144 - Report of proposed sale of securities
10/12/202422:59EDGAR2Form 144 - Report of proposed sale of securities
10/12/202422:58EDGAR2Form 144 - Report of proposed sale of securities
10/12/202422:55EDGAR2Form 144 - Report of proposed sale of securities
03/12/202422:35EDGAR2Form 144 - Report of proposed sale of securities
19/11/202422:08EDGAR2Form 144 - Report of proposed sale of securities
14/11/202422:19EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
14/11/202422:01GLOBEAscendis Pharma Reports Third Quarter 2024 Financial Results
14/11/202419:28EDGAR2Form SC 13G/A - Statement of Beneficial Ownership by Certain..
14/11/202415:31EDGAR2Form SC 13G/A - Statement of Beneficial Ownership by Certain..
13/11/202422:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
07/11/202422:01GLOBEAscendis Pharma to Report Third Quarter 2024 Financial..
04/11/202413:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
04/11/202413:00GLOBEAscendis Pharma and Novo Nordisk Sign Collaboration for..
09/10/202422:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
30/9/202414:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
30/9/202414:30GLOBEAscendis Pharma Announces Submission of Supplemental..
27/9/202422:59EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
23/9/202422:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20/9/202422:01EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
20/9/202402:16GLOBEAscendis Pharma A/S Announces Pricing of Public Offering of..
18/9/202423:20EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
18/9/202422:04GLOBEAscendis Pharma A/S Announces Proposed Public Offering of..
18/9/202422:01EDGAR2Form F-3ASR - Automatic shelf registration statement of..
16/9/202413:32EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
16/9/202413:28EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
16/9/202413:00GLOBEPivotal ApproaCH Trial of TransCon™ CNP (Navepegritide)..
13/9/202414:30GLOBEAscendis to Present First Results from Platinum-Resistant..
11/9/202423:37GLOBEAscendis Pharma Receives Orphan Drug Exclusivity in the..
11/9/202422:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
04/9/202411:50IHMARKETNEWSNvidia Subpoenaed by DOJ, Athira Pharma Shares Plunge 71%..
03/9/202423:14EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
03/9/202423:14GLOBERoyalty Pharma and Ascendis Pharma Enter Into $150 Million..
03/9/202423:11EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
03/9/202423:10EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
03/9/202423:06GLOBEAscendis Pharma and Royalty Pharma Enter into $150 Million..
03/9/202423:04GLOBEAscendis Pharma Reports Second Quarter 2024 Financial..
28/8/202414:30GLOBEAscendis Pharma to Report Second Quarter 2024 Financial..
13/8/202411:43IHMARKETNEWSDell Stock Slide Offers Opportunities; Trump and Musk hold..
Apertura: Min: Max:
Chiusura: 134,04

La tua Cronologia

NASDAQ
ASND
Ascendis Pharma AS
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network